SOUTH SAN FRANCISCO, CA, Sep. 8, 2009 (Marketwire) --
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 09/08/09 -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that data relating to two Phase IIa clinical trials evaluating omecamtiv mecarbil (formerly CK-1827452), one in stable heart failure patients and one in patients with ischemic cardiomyopathy and angina, are scheduled to be presented in three poster presentations at the 2009 Heart Failure Society of America Annual Meeting, to be held September 13-16, 2009 at the John B. Hynes Veterans Memorial Convention Center in Boston, Massachusetts.
Poster Presentations
Abstract #213: "An Analysis of the Response to CK-1827452, a Selective Cardiac Myosin Activator, in Stable Heart Failure Patients Stratified by Baseline Cardiac Function" is scheduled to be displayed on Monday, September 14, 2009 from 9 AM - 7 PM Eastern Daylight Time (EDT) in Exhibit Hall C. The poster will be moderated by Fady Malik, MD, PhD, FACC, Vice President, Biology and Therapeutics, Cytokinetics, Inc., South San Francisco, California from 5:45-6:45 PM EDT.
Abstract #219: "Phase II Safety Study Evaluating the Novel Cardiac Myosin Activator, CK-1827452, in Patients with Ischemic Cardiomyopathy and Angina" is scheduled to be displayed on Tuesday, September 15, 2009 from 9 AM - 7 PM Eastern Daylight Time (EDT) in Exhibit Hall C. The poster will be moderated by Will Chou, MD, Medical Director, Cytokinetics, Inc., South San Francisco, California from 5:45-6:45 PM EDT.
Abstract #227: "Echocardiographic Detection of Increases in Ejection Fraction in Patients with Heart Failure Receiving the Selective Cardiac Myosin Activator, CK-1827452" is scheduled to be displayed on Tuesday, September 15, 2009 from 9 AM - 7 PM Eastern Daylight Time (EDT) in Exhibit Hall C. The poster will be moderated by Jonathan Goldman, MD, FACC, Chief Medical Officer and Senior Vice President, ICON Medical Imaging, Warrington, Pennsylvania from 5:45-6:45 PM EDT.
About Cytokinetics
Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Cytokinetics' cardiac muscle contractility program is focused on cardiac muscle myosin, a motor protein essential to cardiac muscle contraction. Cytokinetics' lead compound from this program, omecamtiv mecarbil (formerly CK-1827452), a novel small molecule cardiac muscle myosin activator, is in Phase II clinical trials for the potential treatment of heart failure. In May 2009, Amgen Inc. exercised an option to obtain an exclusive worldwide (excluding Japan) license to this program, which includes rights to develop and commercialize omecamtiv mecarbil and related compounds.
